Eli Lilly Unveils Affordable Single-Dose Zepbound Vials to Boost US Supply
Eli Lilly has introduced single-dose vials of its weight-loss drug Zepbound in the United States, specifically targeting patients without insurance coverage for the medication. The new 2.5 mg and 5 mg vials are available through LillyDirect at list prices of $399 and $549 per month, respectively. This move aims to address the high demand and current shortages of obesity medications, as reported by the FDA, and to offer a more affordable option for patients paying out of pocket.
The release of these lower-dose vials is expected to significantly boost the availability of Zepbound and other obesity treatments. The pricing strategy also provides a direct purchasing option via LillyDirect, bypassing third-party supply chains and offering transparent pricing. However, these vials will require patients to manually draw the medication using a syringe, which might not be as convenient as the pre-filled injector pens. This initiative is part of Lilly's broader effort to expand access to its weight-loss drug amid increasing competition from cheaper, compounded versions.
